Article info

Extended report
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

Authors

  1. Correspondence to Dr Lisy Wang, Department of Clinical Sciences, Pfizer Inc, 445 Eastern Point Road, Groton, CT 06340, USA; Lisy.Wang{at}pfizer.com
View Full Text

Citation

Curtis JR, Lee EB, Kaplan IV, et al
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

Publication history

  • Received May 2, 2014
  • Revised March 5, 2015
  • Accepted March 22, 2015
  • First published April 22, 2015.
Online issue publication 
June 08, 2018

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.